NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Enara Bio

Enara Bio

Private
OxfordHealthcare & Life Scienceshttps://enarabio.com/

Last Round

Series B

Oct 3, 2024

Total Funding Raised

$84.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Enara Bio is a biotechnology company that develops cancer immunotherapies by utilizing its proprietary platforms to discover and validate novel cancer-specific targets known as Dark Antigens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

immunotherapyT-cell receptorTCRcancer drug discoverydark antigensTCR-T cell therapycomputational biologydrug discovery platformsolid tumor therapybiotech discovery engineAI drug discoveryprecision medicineproteomicsin silico drug discoverybiopharma partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enara Bio Comparables

Compare Enara Bio with similar companies based on industry and business-model similarity.

Enara Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
T-Therapeutics
84%
T-Knife
81%
BlueSphere Bio
79%

Enara Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 3, 2024
Series ANov 6, 2019

Key People

Founding team and executive leadership

Kevin Pojasek

President, CEO And Board Director

Executive Team

Stacey Davis

CBO & CFO

Executive Team

Enara Bio Investors

Notable investors and investment history

Enara Bio investors
InvestorRounds
RA Capital ManagementSeries B, Series A, Series A Extension
SV Health InvestorsSeries B, Series A Extension, Series A
M VenturesSeries B
The Francis Crick InstituteSeries B
Pfizer VenturesSeries B
Samsara BioCapitalSeries B, Series A, Series A Extension
Pfizer VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Monthly visitors increased 81% MoM, reaching 3.5K.

  • Mar 18, 2026

    New data on lead candidate ENA101 to be presented, targeting novel cancer antigen.

Enara Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enara Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enara Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range68
Year Founded2016
Last FundingOct 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.